Clinical Trial Update: Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy [Phase 2]

View source ↗

Summary

Phase II trial evaluating the MEGO combination (mitoxantrone, etoposide, gemtuzumab ozogamicin) in acute myeloid leukemia patients refractory to initial inducti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Etoposide (Etoposide)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: Robert Redner, MD | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2024-04-18